Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (26) ·
Monoamine releasing agent (9) ·
GABAA positive allosteric modulator (8) ·
CB1/CB2 agonist (7) ·
Dopamine/norepinephrine reuptake inhibitor (5) ·
Potent 5-HT2A agonist (5) ·
LSD analogue; 5-HT2A agonist (4) ·
Prodrug of LSD; 5-HT2A agonist (4) ·
Serotonin/norepinephrine/dopamine releasing agent (3) ·
None (2) ·
Cathinone analogue; monoamine reuptake inhibitor (2) ·
Dopamine and norepinephrine reuptake inhibitor (2) ·
NMDA antagonist (2) ·
Prodrug of GHB (2)
uses:
None (131) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
'"`UNIQ--vote-00000013-QINU`"' (1) ·
'"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"' (1) ·
'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' (1) ·
'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (1)
starting dose:
None (131) ·
ADHD (Kapvay ER): 0.1 mg PO at bedtime, titrate weekly to 0.4 mg/day divided BID. HTN (IR): 0.1 mg PO BID, titrate by 0.1 mg increments (1) ·
ADHD: 30 mg PO once daily in the morning; titrate by 10-20 mg weekly to clinical effect. Binge-eating disorder: 30 mg/day, titrate to 50-70 mg/day (1) ·
Children ≤70 kg: 0.5 mg/kg/day, titrate to 1.2 mg/kg/day after 3 days. Adults and children >70 kg: 40 mg PO once daily for 3 days, then 80 mg/day, then if needed 100 mg/day after 2-4 weeks (1) ·
Intuniv ER 1 mg PO once daily; titrate by 1 mg/week as tolerated to clinical response (1) ·
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)
preparations:
None (131) ·
Capsules 10, 18, 25, 40, 60, 80, 100 mg (1) ·
Capsules 10, 20, 30, 40, 50, 60, 70 mg; chewable tablets 10, 20, 30, 40, 50, 60 mg (1) ·
Extended-release tablets 1, 2, 3, 4 mg (Intuniv); immediate-release tablets 1, 2 mg (Tenex) (1) ·
Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1) ·
IR tablets 0.1, 0.2, 0.3 mg; ER tablets 0.1, 0.2 mg (Kapvay); transdermal patches 0.1, 0.2, 0.3 mg/24h (TTS-1/2/3, weekly); epidural injection (Duraclon) (1)
fda max:
None (131) ·
100 mg/day (adult); 1.4 mg/kg/day or 100 mg total (pediatric, whichever lower) (1) ·
2.4 mg/day (HTN, IR); 0.4 mg/day (ADHD, Kapvay) (1) ·
7 mg/day in children and adolescents; weight-based ceiling (~0.12 mg/kg/day) applies in smaller patients (1) ·
70 mg/day (1) ·
N/A (never approved) (1)
routes:
onset:
None (131) ·
1-2 hours (slower than immediate-release amphetamine because activation requires enzymatic cleavage in red blood cells) (1) ·
30-60 min (IR oral); 2-3 days to steady state (transdermal patch) (1) ·
ADHD effect emerges over 1-2 weeks (slower than psychostimulants); full effect 4-6 weeks (1) ·
Gradual; full clinical effect over 2-4 weeks of titration (1) ·
~20–40 min PO; faster sublingual/intranasal. (1)
duration:
None (131) ·
10-12 hours (smoother profile than immediate-release amphetamine salts) (1) ·
24 hours (once-daily or split BID dosing) (1) ·
6–10 h subjective; full pharmacologic effect considerably longer. (1) ·
8-12 hours (IR); ~7 days (transdermal patch) (1) ·
~24 hours (ER formulation supports once-daily dosing) (1)
halflife:
None (131) ·
12-16 hours'"`UNIQ--ref-00000026-QINU`"' (1) ·
Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) ·
Parent lisdexamfetamine <1 hour; dextroamphetamine 10-12 hours after release'"`UNIQ--ref-00000017-QINU`"' (1) ·
~17-18 hours (Intuniv ER); ~17 hours (immediate-release)'"`UNIQ--ref-00000020-QINU`"' (1) ·
~5 hours in extensive CYP2D6 metabolizers; ~21 hours in CYP2D6 poor metabolizers'"`UNIQ--ref-00000014-QINU`"' (1)
bioavailability:
None (131) ·
Not formally characterized in humans. (1) ·
~58% (extended-release); ~80% (immediate-release)'"`UNIQ--ref-00000021-QINU`"' (1) ·
~63% (oral; extensive first-pass)'"`UNIQ--ref-00000015-QINU`"' (1) ·
~75-85% (oral); ~60% (transdermal at steady state)'"`UNIQ--ref-00000027-QINU`"' (1) ·
~96% after red blood cell hydrolytic cleavage releases dextroamphetamine'"`UNIQ--ref-00000018-QINU`"' (1)
pregnancy:
None (131) ·
Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) ·
Limited human data. Animal studies show fetal effects at maternally toxic doses; use only if benefits justify the potential risk.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; the amphetamine class is associated with intrauterine growth restriction and neonatal withdrawal symptoms.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Older agent with substantial use experience but limited controlled data; case reports of neonatal sedation and transient hypertension with maternal use near term.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
None (132) ·
[[USLegal:Prescription only|Rx-only]] in US. '''Not a controlled substance''', the principal clinical selling point versus psychostimulant ADHD options. Carries the antidepressant-class '''Boxed Warning''' for suicidal ideation in pediatric patients'"`UNIQ--ref-00000016-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, like guanfacine and unlike the psychostimulant alternatives for ADHD'"`UNIQ--ref-00000028-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, which is a meaningful contrast to the psychostimulant alternatives for ADHD'"`UNIQ--ref-00000022-QINU`"' (1) ·
[[USLegal:Schedule II|Schedule II controlled substance]] in US'"`UNIQ--ref-00000019-QINU`"' (1)
Showing below up to 136 results in range #1 to #136.
1
2
- 2-AI
- 2-FA
- 2-FDCK
- 2-FMA
- 25B-NBOH
- 25B-NBOMe
- 25C-NBOH
- 25C-NBOMe
- 25I-NBOH
- 25I-NBOMe
- 25N-NBOMe
- 2C-B-FLY
- 2C-C
- 2C-D
- 2C-E
- 2C-I
- 2C-P
- 2C-T-2
- 2C-T-7
3
4
5
A
B
C
D
E
F
G
H
I
J
L
M
- MCPP
- MDPV
- Mephedrone
- MET
- Methallylescaline
- Methcathinone
- Methoxetamine
- Methylnaphthidate
- Methylone
- Metizolam
- Mexedrone
- MiPLA
- MiPT